

July 9, 2014



BioCorRx, Inc. Eliminates Nearly \$1,000,000 of Convertible Debt

Some Debt Strategically Converted to License Agreements

Los Angeles, July 9, 2014 (GLOBE NEWSWIRE) -- BioCorRx Inc. ("the Company") (OTCQB: BICX), a leader in addiction treatment and rehabilitation programs, is pleased to announce a series of transactions that strengthens the company's balance sheet and offers future, income-producing upside through the elimination of all convertible debt. In addition, these steps remove any potential stock dilution that may have resulted from a debt to equity conversion of those convertible debentures. The total overall debt and interest, mostly convertible, that has been eliminated in recent transactions is nearly \$750,000. In the first stage of debt reduction initiatives, the company's debt holders agreed to exchange just over \$600,000 in overall debt for upfront license fees towards territories that will give them the exclusive rights to distribute the company's Start Fresh Program which is used to treat alcohol and opioid addiction. These additional territories could generate future income for the company, thereby turning a liability into an asset. Separately, the company paid off debt to another investor in the amount of roughly \$135,000 using company funds. Finally, the company successfully converted its remaining \$543,000 of convertible debentures which included interest into a simple interest-bearing note payable.

"We are very pleased with the support of our debt holders, who agreed to convert their outstanding debt into license agreements or simple interest bearing notes" said Lourdes Felix, CFO of BioCorRx, Inc. "It's a testament to their belief in the future of our company and the effectiveness of our Start Fresh Program in treating addiction. Eliminating nearly \$1 million dollars in convertible debt is a monumental and strategic achievement for the company as it vastly improves the capital structure of BioCorRx as the potential dilutive effect of the debt is removed. We have turned our debt into potential income producing assets that will enhance our goal of making our program available to everyone in the U.S. soon."

Media

[Click here to view Recent National Television Media on the BioCorRx YouTube Channel](#)

[Click here for company Facebook page for more stories and media coverage](#)

About BioCorRx, Inc.

BioCorRx, Inc. (OTCQB: BICX) is an addiction treatment and rehabilitation company on the leading edge of addiction treatment. The company has developed a highly effective program called the Start Fresh Program™ consisting of two components used by various addiction clinics in the US. Clinic reports show that the treatment program has an extremely high

success rate with individuals that complete the program. The first component of the program consists of an outpatient implant procedure performed by a licensed physician that delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component of the program developed by BioCorRx, Inc. is a one on one coaching program specifically tailored for the treatment of alcoholism and other substance abuse addictions. For more information on BICX, visit www.BioCorRx.com.

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

CONTACT: Investor Relations

SmallCapVoice.com, Inc.

512-267-2430

Source: BioCorRx